About the Company
We do not have any company description for Proteostasis Therapeutics Inc at the moment.
Please visit http://www.proteostasis.com/ for more information about the company.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PTI News
Harold R Werner's Net Worth
Who is Harold R Werner? Harold R Werner has an estimated net worth of $90.4 Million. This is based on reported shares across multiple companies, which include DIACRIN INC /DE/, TETRALOGIC ...
EFTR eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...
Bihua Chen's Net Worth
Bihua Chen has an estimated net worth of $1.18 Billion. This is based on reported shares across multiple companies, which include Corbus Pharmaceuticals Holdings, Inc., MoonLake Immunotherapeutics ...
Intellia Therapeutics Inc NTLA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
ONTX Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage ...
Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results
Warning! GuruFocus has detected 2 Warning Sign with DNLI. Denali Therapeutics Inc (NASDAQ:DNLI) released its 8-K filing on February 27, 2024, detailing its financial results for the fourth quarter ...
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a ...
Viking Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript February 28, 2024 Voyager Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.25, expectations were $-0.59.
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...
Loading the latest forecasts...